Birdwatch Archive

Birdwatch Note

2025-05-09 17:22:59 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

William Makis lost his medical license in 2019 due to unprofessional conduct. He does not treat cancer patients. https://search.cpsa.ca/Complaints?fn=023044-000019262482-OT https://jssbarristers.ca/rules/makis-v-college-of-physicians-and-surgeons-of-alberta-complaint-review-committee/ Ivermectin has shown anticancer effects in laboratory cells and mice. However, robust evidence in humans is lacking https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079 https://healthfeedback.org/claimreview/lack-evidence-cancer-treatment-protocol-recommends-antiparasitic-drugs-ivermectin-mebendazole/ https://www.poynter.org/fact-checking/2025/ivermectin-cure-cancer-parasite/ https://www.anticancerfund.org/en/blog/separating-fact-fiction-repurposed-drugs-cancer-treatment

Written by 2A6B630D0AEA2ACC36E2189A989B042C8F44788D5C6526EF4EAC8856A79A73D8
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1920806221747023896

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1920892265972519253
  • noteId - 1920892265972519253
  • participantId -
  • noteAuthorParticipantId - 2A6B630D0AEA2ACC36E2189A989B042C8F44788D5C6526EF4EAC8856A79A73D8
  • createdAtMillis - 1746811379318
  • tweetId - 1920806221747023896
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 0
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • William Makis lost his medical license in 2019 due to unprofessional conduct. He does not treat cancer patients. https://search.cpsa.ca/Complaints?fn=023044-000019262482-OT https://jssbarristers.ca/rules/makis-v-college-of-physicians-and-surgeons-of-alberta-complaint-review-committee/ Ivermectin has shown anticancer effects in laboratory cells and mice. However, robust evidence in humans is lacking https://apnews.com/article/fact-check-ivermectin-nih-cancer-cure-629592291079 https://healthfeedback.org/claimreview/lack-evidence-cancer-treatment-protocol-recommends-antiparasitic-drugs-ivermectin-mebendazole/ https://www.poynter.org/fact-checking/2025/ivermectin-cure-cancer-parasite/ https://www.anticancerfund.org/en/blog/separating-fact-fiction-repurposed-drugs-cancer-treatment

Note Ratings

rated at rated by
2025-05-10 09:53:56 -0500 Rating Details
2025-05-10 03:21:40 -0500 Rating Details
2025-05-10 00:46:42 -0500 Rating Details
2025-05-09 15:07:57 -0500 Rating Details
2025-05-09 13:45:27 -0500 Rating Details
2025-05-09 13:16:31 -0500 Rating Details
2025-05-09 13:11:20 -0500 Rating Details
2025-05-09 12:54:32 -0500 Rating Details
2025-05-10 05:24:09 -0500 Rating Details
2025-05-10 00:58:26 -0500 Rating Details
2025-05-09 17:29:42 -0500 Rating Details
2025-05-09 15:42:10 -0500 Rating Details
2025-05-09 15:36:23 -0500 Rating Details
2025-05-09 15:22:17 -0500 Rating Details
2025-05-09 15:02:45 -0500 Rating Details
2025-05-09 13:35:21 -0500 Rating Details
2025-05-09 18:59:36 -0500 Rating Details
2025-05-09 18:57:04 -0500 Rating Details
2025-05-09 16:48:19 -0500 Rating Details
2025-05-09 16:13:59 -0500 Rating Details
2025-05-09 12:25:40 -0500 Rating Details
2025-05-10 13:37:02 -0500 Rating Details
2025-05-09 14:34:33 -0500 Rating Details
2025-05-09 15:33:37 -0500 Rating Details
2025-05-09 14:22:04 -0500 Rating Details
2025-05-09 13:49:11 -0500 Rating Details
2025-05-10 00:45:30 -0500 Rating Details
2025-05-09 18:26:39 -0500 Rating Details
2025-05-09 16:57:37 -0500 Rating Details
2025-05-09 15:12:05 -0500 Rating Details
2025-05-09 14:04:47 -0500 Rating Details
2025-05-09 13:08:04 -0500 Rating Details
2025-05-09 18:59:58 -0500 Rating Details
2025-05-09 18:15:53 -0500 Rating Details
2025-05-09 17:32:54 -0500 Rating Details
2025-05-09 14:58:55 -0500 Rating Details
2025-05-09 13:05:26 -0500 Rating Details
2025-05-09 12:57:47 -0500 Rating Details
2025-05-09 16:15:47 -0500 Rating Details
2025-05-09 15:14:34 -0500 Rating Details
2025-05-09 14:44:10 -0500 Rating Details
2025-05-09 13:48:13 -0500 Rating Details
2025-05-12 21:18:37 -0500 Rating Details
2025-05-10 03:26:14 -0500 Rating Details
2025-05-09 18:15:03 -0500 Rating Details
2025-05-09 17:06:07 -0500 Rating Details
2025-05-09 13:23:16 -0500 Rating Details
2025-05-09 13:05:15 -0500 Rating Details
2025-05-09 23:36:56 -0500 Rating Details
2025-05-09 18:11:50 -0500 Rating Details
2025-05-09 16:43:28 -0500 Rating Details
2025-05-09 16:14:44 -0500 Rating Details
2025-05-09 14:19:58 -0500 Rating Details
2025-05-09 14:16:35 -0500 Rating Details
2025-05-09 13:12:52 -0500 Rating Details
2025-05-09 17:20:48 -0500 Rating Details
2025-05-09 17:11:43 -0500 Rating Details
2025-05-09 13:15:22 -0500 Rating Details
2025-05-09 16:19:50 -0500 Rating Details
2025-05-11 22:30:50 -0500 Rating Details
2025-05-09 17:17:01 -0500 Rating Details
2025-05-09 13:43:33 -0500 Rating Details
2025-05-13 21:08:44 -0500 Rating Details
2025-05-09 18:57:02 -0500 Rating Details
2025-05-09 17:27:57 -0500 Rating Details
2025-05-09 14:02:37 -0500 Rating Details
2025-05-09 13:32:13 -0500 Rating Details
2025-05-09 15:43:57 -0500 Rating Details
2025-05-09 14:59:50 -0500 Rating Details
2025-05-09 14:44:01 -0500 Rating Details
2025-05-10 01:58:28 -0500 Rating Details
2025-05-09 18:13:58 -0500 Rating Details
2025-05-09 13:58:27 -0500 Rating Details
2025-05-09 13:15:05 -0500 Rating Details
2025-05-10 02:05:57 -0500 Rating Details
2025-05-09 14:06:31 -0500 Rating Details